Drugs / BG505 SOSIP.664 gp140
BG505 SOSIP.664 gp140
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05983874 | Apr 2024 → Mar 2025 | HIV infectious disease | International AIDS Vaccine Initiative | Unknown | No outcome recorded |
| Phase 1 | NCT05863585 | Jun 2023 → Mar 2024 | HIV infectious disease | International AIDS Vaccine Initiative | Unknown | No outcome recorded |
| Phase 1 | NCT04177355 | Jan 2020 → Nov 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03699241 Comparator | Dec 2018 → Mar 2023 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG505 SOSIP.664 gp140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05983874 ↗ |
| Known as | BG505 SOSIP.664 gp140 Vaccine | “Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine” NCT03699241 ↗ |
| Known as | BG505 SOSIP.664 gp140 Vaccine, Adjuvanted | “BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage” NCT05983874 ↗ |
| Modality | Vaccine | “Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine” NCT03699241 ↗ |
| Route | Intramuscular | “BG505 SOSIP.664 gp140 is a stable, soluble, cleaved HIV envelope trimer formulated in 0.55mL at 2mg/mL in 20 mM Tris, 100mM Sodium Chloride (NaCl), pH 7.5 and will be...” NCT05983874 ↗ |